Last updated on October 2019

This is an Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus (Itch) and Psoriasis in Subjects Being Treated with Calcipotriene Ointment.


Brief description of study

This study is being done to evaluate the safety and tolerability of SNA-120 0.5% ointment applied with calcipotriene 0.005% ointment. This study will also evaluate the efficacy (effectiveness) of SNA-120 0.5% ointment applied with calcipotriene 0.005% ointment in the treatment of psoriasis and the associated symptoms of itching. The results will be compared against a vehicle. The vehicle is a moisturizing ointment that looks like the SNA-120 but does not contain an active ingredient. 

SNA-120 is an experimental drug, which means it is not yet approved by Health Canada or the United States (US) Food and Drug Administration. It is not approved for use outside of studies like this one. The active ingredient of SNA-120 ointment may inhibit itching in psoriasis patients. Calcipotriene ointment is marketed in the United States for the treatment of plaque psoriasis. You will receive it as if your regular doctor would have prescribed it to you outside this research study.  

There is a 50% chance of having the vehicle ointment instead of the SNA-120 ointment. For this study, a mandatory blood collection will be performed.

The financial compensation for study related expenses will be up to $760.00 if all visits are completed.

The study will last a period of up to 19 weeks. There will be 8 on site visits whose duration will vary from 1-3 hours long and 2 phone call visits of approximately 15-30 minutes.

Clinical Study Identifier: TX207225

Find a site near you

Start Over

Center for Clinical Studies

1401 Binz Street, Suite 200 Houston, TX USA
  Connect »